Switching off cellular recycling gene increases yields of hard-to-make drug target proteins
With an unusual genetic modification that disabled cells' recycling systems, researchers found a way to make cells produce significantly larger amounts of the proteins used to.
Key points
- Focus: With an unusual genetic modification that disabled cells' recycling systems, researchers found a way to make cells produce significantly larger
- Detail: Science reporting: verify primary technical documentation
- Editorial reading: science reporting; whenever possible, verify the cited primary source.
With an unusual genetic modification that disabled cells' recycling systems, researchers found a way to make cells produce significantly larger amounts of the proteins used to discover and develop new medicines. The science-journalism coverage adds useful context, while the strongest evidential footing still comes from the underlying data, papers or institutional documentation.
The significance lies in biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: Add to Preferred Sources Cell Systems (2026).
Overview of gene identification via small-molecule screening and effect of ULK1 KO on mRNA expression levels and recombinant protein expression levels. Even though membrane proteins are the targets of about 60% of approved medicines, they're notoriously difficult to manufacture in useful quantities.
The result was increased production of three difficult-to-make target proteins, GIPR, GPR75 and P2X3, by 30%, 80% and 100%, respectively. Rather than follow the well-worn path of trying to boost the production machinery in cells, the team instead disabled what Rockberg calls a cell's "cleanup crew"—or more.
ULK1 initiates autophagy, the process by which cells break down and recycle proteins and organelles. The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes,".
The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.
Alice Karlsson et al, ULK1 knockout increases recombinant transcript abundance and improves recombinant membrane protein expression, Cell Systems (2026). BA art history, MA material culture.
Because this item comes through Phys. org Biology as science journalism, it should be treated as contextual reporting rather than primary evidence. Good science reporting can identify why a result matters, connect it to the wider literature and make technical work readable, but the decisive evidence remains in the original paper, dataset, mission release or technical record. That distinction is especially important when a story is later repeated by aggregators, because repetition increases visibility, not evidential strength.
The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Original source: Phys. org Biology